Eosinophilic Granulomatous Vasculitis research hub

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

This study compares two treatments, benralizumab and mepolizumab, for a rare condition called Eosinophilic Granulomatosis with Polyangiitis (EGPA). Researchers want to see which one works better and is safer for people whose EGPA keeps coming back or isn't well controlled, even with other medicines.